MedPath

A Study of a Whole-Body Balm on Newborn Babies

Not Applicable
Completed
Conditions
Healthy
Interventions
Other: Whole-body Balm
Other: Wash and Shampoo
Registration Number
NCT05786209
Lead Sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Brief Summary

The purpose of this study is to evaluate the skin tolerance, instrumental efficacy, and perceived product efficacy of a whole-body balm on newborns (0-28 days old).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria

Newborn participants only:

  • Male or Female
  • 0 to 3 months old, targeting at least 15 subjects in the 0 - 28 days age range at time of enrollment.
  • Has Parent Participant-reported Natural Skin tone/skin Color As Follows, including: (a) Skin tones "Pale/fair to light white" and/or "White to light beige" approximately 10 participants; (b) Skin tones "Beige to light tan/light olive" and/or "Medium tan/medium olive to light brown" approximately 10 participants; (c) Skin tones "Medium brown to dark brown" and/or "Darkest brown to darkest black" approximately 10 participants
  • Full term (37 plus weeks of gestation, both vaginal and Caesarean mode of delivery can be included) newborn

Newborn participant and parent participant:

  • Generally, in good health based on medical history reported by the parent participant

Parent participant only:

  • Able to read, write, speak, and understand English
  • At least 18 years old and is the parent (adoptive or biological), legal guardian, and primary caregiver of the newborn participant
  • Has signed the informed consent document (ICD) including Health Insurance Portability and Accountability Act (HIPAA) disclosure
  • Intends to complete the study and is willing and able to follow all study instructions
Exclusion Criteria

Newborn participant only:

  • Presents with a skin condition that may influence the outcome of the study or increase risk to the newborn participant (example , psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer)
  • Has a family history of (defined as having a biological parent or full sibling with) eczema/atopic dermatitis
  • Has been bathed within 3 hours prior to Visit 1
  • Has a clinical grade greater than 0 for rash/irritation, or greater than or equal to 1 for any of the other clinically assessed tolerance parameters at Visit 1

Newborn participant and parent participant:

  • Has known allergies or adverse reactions to common topical skincare products
  • Has self-reported (for the parent participant) or parent participant reported (for the newborn participant) Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication
  • Is taking a medication that would mask an AE or confound the study results, including (a) Immunosuppressive or steroidal drugs within 3 months before Visit 1; (b) Non-steroidal anti-inflammatory drugs within 5 days before Visit 1; (C) Antihistamines within 2 weeks (14 days) before Visit 1

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Whole-body Balm + Wash and ShampooWash and ShampooParent participant will be instructed to apply the whole-body balm on the newborn baby's whole body (excluding the mouth, eyes, diaper area, and scalp) two times per day (morning and evening), and to cleanse the newborn baby with the wash and shampoo at least once per week and no more than three times per week up to Day 28.
Whole-body Balm + Wash and ShampooWhole-body BalmParent participant will be instructed to apply the whole-body balm on the newborn baby's whole body (excluding the mouth, eyes, diaper area, and scalp) two times per day (morning and evening), and to cleanse the newborn baby with the wash and shampoo at least once per week and no more than three times per week up to Day 28.
Primary Outcome Measures
NameTimeMethod
Change From Baseline After 4 Weeks of Product Use in Clinical and Parental Evaluations of Skin tolerance MeasuresChange from baseline after 4 weeks

Change from baseline after 4 weeks of product use in clinical and parental evaluations of skin tolerance measures will be reported. The clinical and parental evaluations of tolerance will be recorded on paper source documentation.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline After 7 Days of Product Use in Corneometer and Transepidermal Water Loss (TEWL) MeasurementsChange from baseline after 7 days

Change from baseline after 7 days of product use in Corneometer and TEWL measurements will be reported. The Corneometer measures moisture content in the stratum corneum by an electrical capacitance method. Readings are proportional to the dielectric constant of the surface layers of the skin, and the results are displayed in arbitrary "Corneometer units" ranging from 0 to 120, with increasing values corresponding to more hydrated skin. TEWL is a equipment with open chamber TEWL probes to measure the TEWL of the skin. The non-invasive probe contains two sensors that measure the temperature and relative humidity at two fixed points along the axis normal to the skin surface.

Change From Baseline After 7 Days of Product Use in Clinical and Parental Evaluations of Skin Tolerance MeasuresChange from baseline after 7 days

Change from baseline after 7 days of product use in clinical and parental evaluations of skin tolerance measures will be reported. The clinical and parental evaluations of tolerance will be recorded on paper source documentation.

Percentage of All Response Options for Each Question in the Parental QuestionnaireDay 28

Percentage of all response options for each question in the parental questionnaire will be reported. parental questionnaire will be completed by the parent participants which include the questions about "how much do you agree after using balm" where 1 indicates 'strongly disagree', 2 indicates 'somewhat disagree', 3 indicates ;neither agree or disagree', 4 indicates 'somewhat agree', 5 indicates 'strongly agree'.

Change From Baseline After 4 Weeks of Product Use in Corneometer and Transepidermal Water Loss (TEWL) MeasurementsChange from baseline after 4 weeks

Change from baseline after 4 weeks of product use in Corneometer and TEWL measurements will be reported. The Corneometer measures moisture content in the stratum corneum by an electrical capacitance method. Readings are proportional to the dielectric constant of the surface layers of the skin, and the results are displayed in arbitrary "Corneometer units" ranging from 0 to 120, with increasing values corresponding to more hydrated skin. TEWL is a equipment with open chamber TEWL probes to measure the TEWL of the skin. The non-invasive probe contains two sensors that measure the temperature and relative humidity at two fixed points along the axis normal to the skin surface.

Number of Response Options for Each Question in the Parental QuestionnaireDay 28

Number of response options for each question in the parental questionnaire will be reported. Parental questionnaire will be completed by the parent participants which include the questions about "how much do you agree after using balm" where 1 indicates 'strongly disagree', 2 indicates 'somewhat disagree', 3 indicates ;neither agree or disagree', 4 indicates 'somewhat agree', 5 indicates 'strongly agree'.

Trial Locations

Locations (1)

CenExcel JBR

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath